Medical Aesthetics: A Untapped Pharma Market With Incoming Competition

Medical aesthetics is a unique biopharmaceutical niche that may scare off companies due to the consumer marketing and doctor relationship-building skills needed to compete in this market, but the potential for growth keeps major players engaged and searching for new technology.

Anti-aging aesthetic medical treatment. 3d illustration of plastic surgery.Mesh and lines in the skin and procedure to eliminate wrinkles
One of biggest challenges for all biopharma players in medical aesthetics is to grow overall market • Source: Shutterstock

Allergan PLC is the dominant player in medical aesthetics with its blockbuster wrinkle-reducing neurotoxin Botox (onabotulinumtoxinA) and portfolio of injectables, implants and other products, but it is not alone. Merz Pharmaceuticals GMBH and Galderma SA also have spent years curating collections of products to entice doctors who are seeing surging interest from patients in non-invasive procedures to improve their appearance.

One of the biggest challenges for all biopharma players in medical aesthetics is to grow the overall market. Allergan's research...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip